Annovis Bio, Inc. Common Stock (ANVS)

Annovis Bio (NYSE: ANVS) announced it will initiate an open-label extension study in January 2026 to further evaluate the long-term safety and efficacy of buntanetap in patients with Parkinson disease. The study will provide continued access to buntanetap for participants from prior clinical trials while enabling extended monitoring of safety outcomes, sustained effects on motor and cognitive function, and the collection of biomarker data to support further evaluation of buntanetap’s potential as a disease-modifying therapy for neurodegenerative disorders.

Enrollment will begin in January 2026

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer disease and Parkinson disease, will host a corporate update webinar followed by a live question-and-answer session. The webinar will feature President and Chief Executive Officer Maria Maccecchini, Ph.D., who will provide an overview of recent company progress, ongoing clinical programs and strategic direction.

MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease, said it will present at the 2025 Annual Meeting of the Parkinson Study Group, held Dec. 4–6 in San Diego. The presentation will expand on recent Phase 3 Parkinson’s biomarker results showing that patients with amyloid co-pathology experience more severe cognitive decline that is reversed by buntanetap, which also reduces tau biomarkers linked to disease progression. Annovis will also debut a cross-study comparison of all completed trials, offering the most comprehensive view to date of cognitive outcomes across indications and underscoring that patients with amyloid pathology achieve the greatest cognitive benefit, supporting the Company’s strategic path forward.

MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will present at the 2025 Annual Meeting of the Parkinson Study Group (PSG), taking place December 4-6, 2025 in San Diego, California.

MALVERN, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced two presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place December 1-4, 2025 in San Diego, California.

On Thursday, there are stocks with unusual volume. Let's take a look.

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the stocks with an unusual volume in today's session.

The meeting with the FDA is scheduled for January 2026.

Annovis Bio (NYSE: ANVS) a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced that the FDA has scheduled a Type C meeting in January 2026 to discuss the clinical pathway for buntanetap in Parkinson’s disease dementia. The Company also reaffirmed continued progress in its Phase 3 Alzheimer’s trial, which remains in full regulatory alignment on design, endpoints and patient population. CEO Maria Maccecchini said the meeting marks an important milestone for the PDD program, with Senior VP Cheng Fang noting that strong data across Alzheimer’s and Parkinson’s studies highlights buntanetap’s potential to address a major unmet need for cognitive decline in Parkinson’s patients.

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END

MarketNewsUpdates News Commentary

MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Type C meeting in January 2026 to discuss the Company's pathway for Parkinson's disease dementia (PDD). Annovis also reaffirmed that its ongoing Phase 3 AD clinical trial continues to progress with full regulatory alignment on study design, endpoints, and patient population.

Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Annovis Bio rises after Phase 3 data show buntanetap halted decline in Parkinson's patients, with results in those with amyloid co-pathology.

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.

Annovis Bio (NYSE: ANVS) released new findings from its Phase 3 early Parkinson’s disease study showing that buntanetap halted cognitive decline across all patients and delivered the strongest benefit in those with mild dementia and amyloid co-pathology, a group representing about 25% of the study population. These patients typically experience faster cognitive deterioration, but treatment with buntanetap reversed this decline and produced measurable reductions in pTau217, total tau and brain-derived tau—biomarkers associated with Alzheimer’s pathology. Annovis noted that the data reinforce its view that neurodegenerative diseases often overlap and require therapies capable of targeting multiple toxic proteins, positioning buntanetap as a potentially broad-acting treatment for cognitive impairment across Parkinson’s and Alzheimer’s disease biology.

Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology showing a three-times greater response

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it will release its third quarter 2025 financial results before market open on Monday, Nov. 17, 2025, followed by a conference call at 8:30 a.m. ET to discuss corporate, financial, and operational updates.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, reported significant third quarter 2025 progress, led by full activation of all 84 sites in its pivotal Phase 3 Alzheimer’s study (NCT06709014) and steady enrollment across the U.S. The company also announced promising biomarker data from its Phase 2/3 Alzheimer’s trial showing strong reductions in inflammation and neurodegeneration, underscoring buntanetap’s disease-modifying potential. Recent achievements include transferring all patents to the new crystal form of buntanetap with IP protection through 2046, publishing supportive pharmacokinetic data, and appointing veteran finance executive Mark Guerin as CFO. “Every element is now aligned as we move toward our data readouts—the final step before an NDA submission,” said Maria Maccecchini, Ph.D., president and CEO.

MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and third quarter 2025 financial results.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, announced that all 84 U.S. sites for its pivotal Phase 3 trial in early Alzheimer’s disease are now fully activated and enrolling, with most already treating patients. The first group of participants has completed the 6-month treatment phase, keeping the company on schedule to deliver symptomatic data in the second half of 2026. CEO Maria Maccecchini said the study, now 25% complete, reflects strong execution and continued momentum toward bringing buntanetap to patients in need of effective therapies.

All 84 clinical sites across the U.S. are fully activated, enrolling, and treating patients